Message from the Board Chair and Executive Director

Dr Manica Balasegaram
Prof Ramanan Laxminarayan

In 2022, the world discovered that antimicrobial resistance (AMR) is now among the leading causes of death globally. A study in The Lancet revealed that nearly 1.3 million people had died of drug-resistant infections in 2019 alone.

GARDP's work has helped bring this situation into even greater focus. In 2022, we made significant strides in developing new treatments for some of the deadliest drug-resistant infections. We also worked to improve access to antibiotics.

World leaders took note of both our work and the pressing need for action. Looking ahead, continued leadership, resources and investment will remain critical. AMR takes more lives each year than malaria and HIV/AIDS combined. But the global community has come together to tackle those and other crises in the past. We can do so again—provided we act now.

Dr Manica Balasegaram
Prof Ramanan Laxminarayan

Each year, up to 214,000 newborns die from an infection resistant to antibiotics. But Orum was one of the lucky ones. After many rounds of treatment at the Kawempe Hospital in Uganda, he survived a life-threatening infection.

Learn more

A global health crisis

Global deaths in 2019 (millions)

10 Cancer
9.14 Heart disease
6.6 Stroke
Direct deaths 1.27 4.95 Associated deaths Antibiotic resistance
0.6 HIV
0.6 Malaria

A landmark study published in January 2022 revealed the true toll of antibiotic resistance for the first time. This health threat now claims more lives than HIV and malaria.

Our mission

Our activities are threefold:

1
Accelerate the development of new and improved treatments for drug-resistant infections
2
Expand
antibiotic access
to all people
3
Connect the antimicrobial
R&D community to fuel innovation

Renewed political commitment

Our efforts to confront antibiotic resistance have gained new momentum. In May, G7 leaders followed Germany's lead, making AMR a priority issue. Many governments have made new or renewed funding commitments to GARDP.

March
£4.5M
Additional investment
from the UK
June
US$1.8M
Funding from Japan,
as part of a
5-year pledge
August
CHF300,000
Grant by the Swiss
Agency for Development
and Cooperation (SDC)
October
€56.7M
Renewed funding from Germany
€400,000
Renewed funding from Monaco
CHF1.2M
New support for SECURE from the Wellcome Trust
CA$300,000
New pledge for SECURE from Canada
December
€14.35M
5-year grant
by the Netherlands

Accelerate antibiotic development

GARDP's portfolio

As we progress towards our goal of developing 5 new treatments by 2025, our pipeline now includes 4 antibiotic treatments, with agreements to facilitate their access in resource-limited settings.

Download portfolio
1
Neonatal sepsis treatment regimen:
to provide new antibiotic combinations for newborns with sepsis
2
Cefiderocol:
to treat serious bacterial infections in adults and children
3
Cefepime-taniborbactam:
to treat serious bacterial infections in adults and children
4
Zoliflodacin:
to treat uncomplicated gonorrhoea

2022 highlights

Children's Antibiotics
Serious Bacterial Infections
Sexually Transmitted Infections
Discovery & Exploratory Research

Children's Antibiotics

Goal

Identify new treatments for newborns and children with drug-resistant infections

LAID the groundwork for a groundbreaking clinical trial (“NeoSep1”) to evaluate three new combinations of older antibiotics in comparison with the current standard of care to treat babies with sepsis.
PREPARED development of new paediatric indications for cefepime-taniborbactam and cefiderocol to treat serious bacterial infections in children.

What's next?
In early 2023, the NeoSep1 trial will start in Kenya and South Africa.

Okwenathi was tiny and fragile when he was born prematurely at Cape Town's Tygerberg Hospital. Already facing health challenges, he picked up an antibiotic-resistant infection and had to fight for his life.

Learn more

Serious Bacterial Infections

Goal

Co-develop a new antibiotic treatment for serious bacterial infections

WELCOMED positive results in Venatorx Pharmaceuticals, Inc.'s phase 3 clinical trial. If approved, cefepime-taniborbactam will be the first new antibiotic treatment developed in collaboration with GARDP.
BEGAN an observational study to assess current treatments for carbapenem-resistant infections in high-burden settings.

What's next?
The observational study will expand in 2023 to include a total of 11 sites across India and South Africa.

Far too often, South African microbiologist Justyna Wojno and her colleagues encounter bacteria that are resistant to antibiotics.

Sexually Transmitted Infections

Goal

Develop a new treatment for gonorrhoea

ADVANCED phase 3 trial of a novel gonorrhoea treatment, zoliflodacin, developed with Entasis Therapeutics Limited. All 16 trial sites across 5 countries are now active and all participants have been recruited.

What's next?
Results are expected in late 2023.

“With more infections, the risk of antimicrobial resistance rises. My great hope for treating STIs in the Netherlands is that we will always stay one step ahead of the bug.”
Henry de Vries, Principal Investigator at the STI Clinic of GGD Amsterdam

Discovery & Exploratory Research

Goal

Identify new substances with potential for drug development

SCREENED more than 20,200 compounds in the search for new antibiotics.
REVIEWED advances in the field and explored new research avenues to identify gaps in the global antibiotic pipeline.

What's next?
In 2023, we will share our findings through review articles in globally recognized journals.

Expand access to antibiotics

2022 highlights

Accelerating access
Secure: The Antibiotic Facility

Accelerating access

Goal

Advance access to antibiotics in GARDP's portfolio

SIGNED landmark license and collaboration agreements with Shionogi & Company, Limited and the Clinton Health Access Initiative (CHAI), to expand access to the antibiotic cefiderocol in 135 countries.
APPLIED for the addition of flomoxef to WHO Model Lists of Essential Medicines with Shionogi, to facilitate flomoxef access in resource-limited settings.

“The cefiderocol license and collaboration agreements take us one step closer to a world in which low- and middle-income countries that need antibiotics to fight resistant infections have the same options as high-income countries.”
Jennifer Cohn, Global Access Director, GARDP

Secure: The Antibiotic Facility

Goal

Accelerate access to essential antibiotics

SECURED seed funding from the Wellcome Trust and a financial pledge from the Canadian government for the SECURE initiative; and launched a new website.

GAINED international recognition by both the G7 and G20 Health Ministers. SECURE was recognized as a key access initiative in the global effort against antibiotic resistance.


Connect the antimicrobial R&D community via REVIVE

2022 highlights

EXPANDED REVIVE, GARDP's online knowledge-sharing platform for the antimicrobial R&D community.

Key numbers

217,727
views
57
webinars
48
Antimicrobial Viewpoint articles
200
Antimicrobial Encyclopaedia entries
10,400
webinar participants
158
REVIVE experts
75
partner organizations around the world

CO-ORGANIZED the annual Antimicrobial Chemotherapy Conference with the British Society for Antimicrobial Chemotherapy. 773 people from 67 countries attended the event.

Tackling antibiotic resistance together

GARDP's work is made possible by our funders, which include governments, private foundations and others who share our view that effective antibiotics are essential to modern healthcare and global health security.

Take action

Global network and R&D partners

GARDP has built a strong team of experts from the private, non-profit, academic and public sectors, who work with DNDi regional offices and partners around the world.

Global network
Neonatal sepsis programme partners
Cefepime-taniborbactam drug project partners
Zoliflodacin drug project partners
Discovery & Exploratory Research programme partners and collaborators

Global network

GARDP Foundation—Headquarters in Geneva
Set up as an independent not-for-profit foundation in 2018, GARDP's headquarters are located in Geneva, Switzerland.
GARDP North America
Established in the US in 2021, this independent organization (501c3) aims to increase awareness, raise funds and advocate for policy change to counter AMR.
Latin America—DNDi regional office in Rio de Janeiro
It supports GARDP's work on surveillance studies of resistance in Latin America.
DNDi—GARDP Southern Africa
Established by DNDi and GARDP in 2018, this independent organization is responsible for the implementation of GARDP's trials and studies in South Africa. It also builds regional networks for advocacy, access and stewardship strategies for antibiotics.
East Africa—DNDi regional office in Nairobi
It assists in GARDP's work in the region, including clinical trials and studies on neonatal sepsis and sexually transmitted infections.
South Asia—DNDi regional office in New Delhi
It supports GARDP's observational studies which will help plan future interventional trials in India. GARDP also works with Indian drug developers and other actors.
Southeast Asia—DNDi regional office in Kuala Lumpur
It assists in GARDP's work in the region, including GARDP's work on sexually transmitted infections in Thailand.
Japan—DNDi Tokyo office
It helps GARDP liaise with Japanese companies and the Japanese government.
Representation in Australia
It links GARDP with companies and the Australian government.

Neonatal sepsis programme partners

Bangladesh
  • Dhaka Shishu Hospital
Belgium
  • University of Antwerp
Brazil
  • FCM da Santa Casa de São Paulo
  • Hospital das Clínicas de Ribeirão Preto
China
  • Shenzhen Children's Hospital
  • Beijing Children's Hospital
  • Beijing Women and Children's Hospital
Germany
  • InfectoPharm
Greece
  • Hippokration Hospital
India
  • All India Institute of Medical Sciences (AIIMS)
  • Lady Hardinge Medical College
  • Jawaharlal Institute of Postgraduate Medical Education & Research (JPIMER)
  • King Edward (VII) Memorial Hospital (KEM)
Italy
  • Bambino Gesù Hospital
  • Penta Foundation
Japan
  • Shionogi & Company, Limited
Kenya
  • Kenyan Medical Research Institute (KEMRI)
  • Kilifi County District Hospitals
South Africa
  • Tygerberg Children's Hospital
  • Chris Hani Baragwanath Academic Hospital
  • Charlotte Maxeke Johannesburg Academic Hospital
Thailand
  • Queen Sirikit National Institute of Child Health
  • Maharaj Nakorn Chiang Mai Hospital
Uganda
  • Mulago National Referral Hospital
United Kingdom
  • University of Liverpool
  • St George's, University of London
  • MRC Clinical Trials Unit, University College London
Vietnam
  • National Hospital of Paediatrics

Cefepime-taniborbactam drug project partners

India
  • Indian Council of Medical Research (ICMR)
  • Sir Ganga Ram Hospital
  • Kasturba Medical College
  • Christian Medical College
  • Tata Medical Center
  • P.D. Hinduja Hospital & Medical Research Centre
  • Jawaharlal Institute of Postgraduate Medical Education & Research (JPIMER)
South Africa
  • DNDi-GARDP Southern Africa (Cape Town)
  • National Institute of Communicable Disease (NICD)
  • Chris Hani Baragwanath Academic Hospital
  • Livingstone Hospital
  • Groote Schuur Hospital
  • Tygerberg Hospital
  • University of Cape Town
  • King Edward Hospital
United States
  • Venatorx Pharmaceuticals, Inc.

Zoliflodacin drug project partners

Belgium
  • Institute of Tropical Medicine (ITM)
India
  • Aurigene Pharmaceutical Services Limited
  • Dr. Reddy's Laboratories Limited
Kenya
  • National AIDS and STI Control Programme (NASCOP)
  • Ministry of Health Kenya
Netherlands
  • GGD Amsterdam - Department of Infectious Diseases, Public Health Service Amsterdam
South Africa
  • National Institute for Communicable Diseases (NICD)
  • Wits Reproductive Health and HIV Institute (Wits RHI)
  • South African Medical Research Council (SAMRC)
  • Botha's Hill Clinical Research Site
  • SAMRC Tongaat Clinical Research Site
  • University of KwaZulu-Natal
  • Foundation for Professional Development (FPD)
Sweden
  • WHO Collaborating Centre, Orebro University Hospital
Switzerland
  • Drugs for Neglected Diseases initiative (DNDi)
  • World Health Organization (WHO)
  • Foundation for Innovative Diagnostics (FIND)
Thailand
  • Thailand Ministry of Public Health (MoPH)
  • Bangrak STIs Center, Division of AIDS and STIs, Department of Disease Control, Ministry of Public Health
  • Silom Community Clinic at the Hospital for Tropical Diseases
  • Institute for HIV Research and Innovation Foundation
  • Thailand MoPH U.S. CDC Collaboration Laboratory
  • Siriraj Institute of Clinical Research (SICRES)
  • Faculty of Medicine Siriraj Hospital, Mahidol University
United States
  • Entasis Therapeutics Limited
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • University of Alabama at Birmingham (UAB)
  • Bell Flower Clinic
  • San Francisco Department of Public Health
  • University of Washington
  • Louisiana State University
  • Jefferson County Department of Health (UAB Satellite site)

Discovery & Exploratory Research programme partners and collaborators

France
  • Lyon office of Evotec International GmbH (German company)
Germany
  • Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)
India
  • TCG Lifesciences Private Limited
Japan

Screening partners:

  • Takeda Pharmaceutical Company Limited
  • Eisai Company, Limited
  • Mitsubishi Tanabe Pharma Corporation
  • Sumitomo Pharma Company, Limited
South Korea
  • Institut Pasteur Korea (IPK)
Switzerland
  • Drugs for Neglected Diseases initiative (DNDi)
  • Medicines for Malaria Venture (MMV)
United Kingdom
  • University of Leeds
  • University of Edinburgh
  • Sandexis Medicinal Chemistry Limited
  • Cyprotex Discovery Limited

Take action

Anyone can be affected by antibiotic resistance. Everyone can play a role in stopping it.

Learn how you can help

Finance

Income

From 2016 to 2022, the total funding commitments and pledges to GARDP were €178M.

This is largely thanks to continued support from government donors over the past seven years.

In 2022, we were able to successfully secure further funding from several partners, including:
Germany
€56.7M
Netherlands
€14.35M(for 5 years)
Japan
USD$1.8M(as part of 5-year pledge)
Swiss Agency for
Development and Cooperation
CHF300,000
Principality of Monaco
€400,000
Wellcome trust
CHF1.2M(for SECURE)
United Kingdom
£4.5M

Total funding commitments and pledges to date:

PUBLIC CONTRIBUTORS FROM 2016: €173M

Germany (BMBF and BMG)
€116.8M
The Netherlands (VWS and DGIS)
€21.9M
The United Kingdom (DFID, DHSC: GAMRIF and NIHR)
€21.3M
Japan (MHLW)
€8.8M
Switzerland (FOPH and SDC)
€1.7M
South African Medical Research Council
€0.9M
The Principality of Monaco
€0.8M
Canton de Genève
€0.5M
Australia (Department of Health)
€0.2M
Grand Duchy of Luxemburg
€0.1M

PRIVATE CONTRIBUTORS FROM 2016: €4.9M

Wellcome Trust
€2.3M
Bill & Melinda Gates Foundation
€1.8M
Médecins Sans Frontières
€0.6M
Leo Model Foundation
€0.2M

Expenditure

The year 2022 saw expenditure rise to €24.3M from €17.4M in 2021.

The number reflects the increased activity and significant progress within the Sexually Transmitted Infections programme in relation to the zoliflodacin phase 3 trial, alongside the continued strengthening of our Access activities.

2022 and 2021 R&D, Access, and Scientific Affairs expenditure1 (€ million)

2021
6.8
1.4
1.7
0.8
0.9
0.6
0.6
Total: 12.8M
2022
9.7
1.9
1.2
1.1
2.4
1.9
0.4
Total: 18.7M
  • Sexually Transmitted Infections
  • Children's Antibiotics – Paediatric
  • Serious Bacterial Infections
  • Scientific Affairs
  • Children's Antibiotics – Neonatal sepsis
  • Discovery & Exploratory Research
  • Access2
  1. Figures include programme coordination and support
  2. All activities related to Access and SECURE

2022 expenses

€24.3M
13%
Non-Social Mission
87%
Social Mission
69%
Research & Development
13%
Fundraising and general administration
10%
International network
8%
Access2
  1. All activities related to Access and SECURE

GARDP's total expenditure since inception in 2016 totals €100.4M

Actual expenditure 2016-2022 (€ million)

1.0
4.0
11.2
18.9
23.7
17.4
24.3
  • Actual expenditure
  • Collaboration with Venatorx Pharmaceuticals, Inc.